Dr. Staskin is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
11 Nevins St
Ste 407
Boston, MA 02135Phone+1 617-787-8181Fax+1 617-787-4644- Is this information wrong?
Education & Training
- Ronald Reagan UCLA Medical CenterUrology, 1984 - 1985
- University of Pennsylvania Health SystemResidency, Urology, 1980 - 1984
- University of California (San Diego) Medical CenterInternship, Transitional Year, 1979 - 1980
- Drexel University College of MedicineClass of 1979
Certifications & Licensure
- MA State Medical License 1985 - 2025
- NY State Medical License 2002 - 2010
- American Board of Urology Urology
Awards, Honors, & Recognition
- Boston Magazine Castle Connolly, 2013
- CMS Meaningful Use Stage 1 Certification eClinicalWorks EHR, eClinicalWorks LLC, 2012-2013
- Top Doctors: New York Metro Area Castle Connolly, 2005-2009
- Join now to see all
Clinical Trials
- Neurotech Vital Compact Versus Itouch Sure Pelvic Floor Exerciser US Start of enrollment: 2015 Apr 01
Publications & Presentations
PubMed
- Real-World Adherence to and Persistence with Vibegron in Patients with Overactive Bladder: A Retrospective Claims Analysis.Benjamin Chastek, Adam Carrera, Christina Landis, Daniel Snyder, Laleh Abedinzadeh, Tim Bancroft, Jeffrey Nesheim, Michael Kennelly, David Staskin> ;Advances in Therapy. 2024 May 1
- Oxybutynin-associated Cognitive Impairment: Evidence and Implications for Overactive Bladder Treatment.Michael B Chancellor, Alvaro Lucioni, David Staskin> ;Urology. 2024 Apr 1
- Plain language summary of safety and symptom improvement with vibegron in people with overactive bladder: results from the EMPOWUR study.David Staskin, Jeffrey Frankel, Steven G Gregg, Susann Varano, Janet Owens-Grillo> ;Journal of Comparative Effectiveness Research. 2023 Sep 1
- Join now to see all
Press Mentions
- Urovant Sciences Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association MeetingMay 16th, 2022
- Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (Vibegron) 75 Mg at 2022 American Urological Association Annual MeetingApril 13th, 2022
- Urovant Sciences Presents Positive Ambulatory Blood Pressure Data Showing That GEMTESA® (Vibegron) 75 Mg in Overactive Bladder Was Not Associated with Statistically Significant or Clinically Meaningful Effects on Blood Pressure or Heart RateSeptember 13th, 2021
- Join now to see all
Hospital Affiliations
- St. Elizabeth's Medical CenterBrighton, Massachusetts
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: